Connected Drug Delivery Devices Market

• The global Connected Drug Delivery devices market size is expected to increase from USD 986.91 million in 2024 to USD 5,087.57 million by 2032, reflecting strong and sustained growth.
• The global connected drug delivery devices market is growing at a CAGR of 23.17% during the forecast period from 2025 to 2032.
• The market of connected drug delivery devices is being primarily driven by the rising prevalence of chronic diseases such as diabetes and asthma, the growth of digital health and remote patient monitoring, technological advancements in device design, and an increase in product development activities among the key market players.
• The leading companies operating in the connected drug delivery devices market include Findair Sp. z o. o., Adherium, Propeller Health, West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, Tandem Diabetes Care, Inc., Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., BD, and others.
• North America is expected to dominate the connected drug delivery devices market due to the region's well-established healthcare infrastructure, high adoption of digital health technologies, and growing focus on patient-centric care. The prevalence of chronic diseases, combined with increasing awareness of medication adherence and strong reimbursement support, further drives demand. Additionally, the presence of major device manufacturers and ongoing technological innovations in smart drug delivery solutions contribute to North America's leading position in the market.
• In the product type segment of the connected drug delivery devices market, the integrated connected devices category is estimated to account for the largest market share in 2024.

Connected Drug Delivery Devices Market Size and Forecasts

Request for unlocking the report of the @ Connected Drug Delivery Devices Market Forecast

Factors Contributing to the Growth of the Connected Drug Delivery Devices Market

• The rising prevalence of chronic diseases such as diabetes, asthma, among others leading to a surge in connected drug delivery devices: The rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular disorders is driving the demand for connected drug delivery devices. These devices help monitor therapy, improve medication adherence, and enable personalized treatment, making them essential tools for managing long-term conditions and enhancing patient outcomes. 
• The Growth of digital health and remote patient monitoring is escalating the market of connected drug delivery devices: The growth of digital health and remote patient monitoring is boosting the connected drug delivery devices market by enabling real-time therapy tracking, data sharing with healthcare providers, and timely intervention. This integration improves patient adherence, optimizes treatment outcomes, and supports the shift toward personalized and home-based healthcare.
• Technological advancements in device design: Technological advancements in device design are boosting the connected drug delivery devices market by making devices smarter, more user-friendly, and data-driven. Innovations such as sensors, Bluetooth connectivity, automated dosing, and integration with mobile apps enhance medication adherence, enable real-time monitoring, and provide valuable insights for personalized patient care.

Connected Drug Delivery Devices Market Report Segmentation

This connected drug delivery devices market report offers a comprehensive overview of the global connected drug delivery devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product (Connected Sensors [Connected Inhaler Sensors and Connectable Injection Sensors] and Integrated Connected Devices [Connected Inhaler Devices and Connected Injectable Devices]), Technology (Bluetooth, Near-Field Communication (NFC), and Others), End-User (Hospitals & Clinics, Homecare Settings, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing connected drug delivery devices market.

Connected drug delivery devices are a class of advanced medical devices that integrate traditional therapeutic interventions with digital technologies and wireless connectivity to improve drug administration, patient adherence, and remote monitoring. These devices are equipped with sensors and can connect to mobile apps, healthcare platforms, or cloud-based systems, typically via Bluetooth or Near Field Communication (NFC).

The overall market for connected drug delivery devices is being collectively boosted by several converging factors. The rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular disorders has increased the demand for solutions that support long-term therapy and improve patient adherence. Simultaneously, the growth of digital health and remote patient monitoring enables real-time tracking and data sharing, enhancing personalized care and treatment outcomes. Technological advancements in device design, including smart sensors, automated dosing, and app connectivity, further improve usability and patient engagement. In addition, increased product development activities by key market players are expanding the range of innovative, connected devices available, driving adoption and strengthening market growth.

Get More Insights into the Report @ Connected Drug Delivery Devices Market Trends

What are the latest Connected Drug Delivery Devices Market Dynamics and Trends?

The rising prevalence of diabetes, asthma, and cardiovascular disorders, combined with rapid growth in digital health and remote patient monitoring, is significantly driving the global connected drug delivery devices market. These technologies are reshaping chronic disease management by improving medication adherence, enabling personalized therapy, and reducing the burden on healthcare systems.

According to DelveInsight (2025), approximately 591 million people worldwide were living with diabetes, and this number is projected to surge to 854 million by 2050, representing a 46% increase, with type 2 diabetes accounting for over 90% of cases. In this context, connected insulin pens, smart pumps, and continuous glucose monitoring (CGM) systems are becoming indispensable for maintaining glycemic control. They enable patients to track blood glucose trends, receive reminders, and adhere to insulin regimens, while allowing healthcare providers to remotely access patient data and fine-tune therapies in real time.

Similarly, an estimated 263 million people globally are affected by asthma, creating a significant market for connected inhalers and nebulizers. These devices monitor medication usage, send alerts for missed doses, and transmit adherence data to clinicians, thereby reducing asthma-related risks and emergency hospitalizations. The integration of these solutions into digital care pathways is improving long-term disease management and quality of life for patients.

The broader growth of digital health and remote patient monitoring (RPM) is amplifying this trend. By leveraging mobile apps, Bluetooth Low Energy (BLE), NFC, and cloud-based platforms, connected drug delivery devices provide real-time visibility into medication usage and patient health metrics. This connectivity enables proactive clinical decision-making, supports home-based care, and reduces the need for frequent hospital visits. For instance, in February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first subcutaneous apomorphine infusion device for Parkinson’s disease motor fluctuations. Such innovations highlight the expanding therapeutic scope of connected devices beyond diabetes and respiratory care.

Looking ahead, the adoption of connected drug delivery devices will continue to accelerate, driven by rising chronic disease prevalence, integration of AI-driven analytics, payer emphasis on value-based care, and patient preference for convenient, at-home solutions. However, the market also faces challenges. Data security and privacy risks, concerns around cybersecurity breaches, and the environmental impact of electronic waste disposal remain critical barriers that stakeholders must address to ensure sustainable adoption.

Overall, the convergence of epidemiological trends, digital health advancements, and evolving care models is expected to propel the connected drug delivery devices market from 2025 to 2032, while industry players focus on overcoming technological and environmental challenges to unlock its full potential.

Connected Drug Delivery Devices Market Segment Analysis

Connected Drug Delivery Devices Market by Product (Connected Sensors [Connected Inhaler Sensors and Connectable Injection Sensors] and Integrated Connected Devices [Connected Inhaler Devices and Connected Injectable Devices]), Technology (Bluetooth, Near-Field Communication (NFC), and Others), End-User (Hospitals & Clinics, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Product: Integrated Connected Devices Category Dominates the Market

The integrated connected devices segment of the connected drug delivery devices market is projected to dominate with a 60% market share in 2024. Within this segment, connected injectable devices are expected to hold the largest share, driven by the widespread adoption of smart insulin pens, auto-injectors, and wearable injectors. These devices are becoming the preferred choice for chronic disease management as they improve medication adherence, ensure precise dosing, and enable real-time monitoring of treatment outcomes.

The incorporation of Bluetooth, NFC, and cloud-based platforms allows connected injectors to seamlessly transmit patient data to healthcare providers, enabling timely clinical interventions, dose optimization, and personalized therapy adjustments. This functionality is particularly impactful for chronic conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis, where frequent and long-term injections are required. By facilitating at-home administration, connected injectable devices also reduce dependency on hospital visits, improving patient convenience and reducing healthcare system burden.

Ongoing technological innovations are further accelerating adoption. Advancements include integrated sensors for dose verification, automated alerts for missed or incorrect doses, AI-driven analytics, and interoperability with mobile health apps and electronic health records (EHRs). For example, in November 2024, Medtronic received FDA clearance for an updated version of its InPen™ app, which introduced a missed meal dose detection feature, helping patients proactively manage adherence in diabetes therapy.

From a market dynamics perspective, increasing global prevalence of chronic diseases, supportive regulatory pathways for digital health devices, and the growing emphasis on value-based healthcare models are fueling the uptake of these solutions. Additionally, rising patient awareness, coupled with payer and provider interest in remote monitoring and outcome-based reimbursement models, is strengthening the position of connected injectors as the leading subcategory within integrated connected devices.

Overall, the convergence of chronic disease epidemiology, digital health integration, and continuous device innovation is solidifying connected injectable devices as the primary growth driver of the integrated connected devices market, reinforcing their role as a cornerstone in the future of connected drug delivery.

By Technology: Bluetooth Dominates the Market

In the technology segment of the connected drug delivery devices market, the Bluetooth category is projected to hold the largest market share of 64% in 2024. The widespread adoption of Bluetooth, particularly Bluetooth Low Energy (BLE), has positioned it as the leading connectivity choice due to its low power consumption, seamless integration with smartphones, and ability to support real-time data transmission. Devices such as smart insulin pens, connected inhalers, and wearable injectors leverage Bluetooth to sync with mobile applications, enabling patients to track adherence, receive personalized reminders, and share treatment data with healthcare providers for remote monitoring and optimized care.

The integration of BLE not only boosts patient engagement and convenience but also enhances clinical outcomes, as it allows for accurate dosing verification, automated alerts for missed doses, and timely intervention by healthcare professionals. For example, in May 2025, Oura introduced the Stelo glucose biosensor, a discreet wearable device worn on the upper arm for up to 15 days. The biosensor uses Bluetooth to provide real-time glucose data, which is integrated into the Oura app alongside other health metrics. This allows users to monitor fluctuations in glucose levels in relation to meals, activities, and daily habits, reinforcing the value of Bluetooth-enabled health ecosystems.

Compared to other connectivity technologies such as NFC and Wi-Fi, Bluetooth remains the preferred standard because of its ubiquity across consumer devices, compatibility with digital health platforms, cost-effectiveness, and scalability in both home and clinical settings. Its ability to operate reliably without continuous internet connectivity also makes it highly practical in regions with limited broadband access, broadening its adoption potential globally.

Looking ahead, the demand for connected drug delivery devices utilizing Bluetooth is expected to accelerate in line with the broader adoption of digital health solutions. Factors such as the rising burden of chronic diseases, increased acceptance of remote patient monitoring, and the shift toward value-based healthcare will further solidify Bluetooth’s position as the dominant connectivity technology in the market. Moreover, ongoing advancements in BLE 5.0 and beyond, offering extended range, faster data rates, and improved energy efficiency, are likely to enhance device performance and expand clinical applications.

By End-User: Hospitals & Clinics Dominate the Market

Hospitals and clinics are emerging as critical drivers of growth in the connected drug delivery devices market, serving as primary adoption hubs for these technologies. With the rising emphasis on precision medicine, personalized care, and outcome-based treatment models, healthcare providers are increasingly incorporating smart insulin pens, connected inhalers, and wearable injectors into their clinical workflows. These devices enable continuous patient monitoring, accurate dose administration, and real-time data sharing between patients and physicians, supporting timely therapy adjustments and reducing the risk of treatment-related complications.

Beyond clinical integration, hospitals and clinics play a central role in patient education and awareness. By offering direct training and support, they help patients understand the value of digital adherence tools and connected devices, encouraging consistent use and long-term compliance with prescribed therapies. This not only improves patient outcomes but also reduces hospital readmissions and overall healthcare costs, aligning with the industry’s shift toward value-based care models.

Moreover, the capacity of hospitals and clinics to generate, manage, and analyze large volumes of patient data enhances evidence-based decision-making and provides valuable real-world insights for clinicians, payers, and device manufacturers. These data-driven capabilities are increasingly important as health systems adopt AI-powered analytics, electronic health record (EHR) integration, and remote monitoring platforms, creating a seamless ecosystem for connected drug delivery devices.

As a result, hospitals and clinics are not only early adopters but also influential stakeholders in scaling adoption, as their validation and integration of connected devices often drive broader acceptance across home care settings, retail pharmacies, and outpatient centers. This positions them as pivotal enablers of market expansion, accelerating the transition toward digitally connected, patient-centric drug delivery.

Connected Drug Delivery Devices Market Regional Analysis

North America Connected Drug Delivery Devices Market Trends

North America is expected to account for the largest share, around 45%, of the connected drug delivery devices market in 2024, supported by the region’s advanced healthcare infrastructure, strong digital health adoption, and growing emphasis on patient-centric care. The high burden of chronic diseases, coupled with rising awareness of medication adherence and favorable reimbursement policies, is accelerating the uptake of smart drug delivery solutions such as connected insulin pens, inhalers, and wearable injectors.

According to the Centers for Disease Control and Prevention (2024), over 38.4 million people (11.6% of the U.S. population) have diabetes, creating a significant demand for insulin therapy. This has amplified the need for connected insulin pens, insulin pumps, and automated delivery systems, which improve adherence, optimize dosing, and enable real-time monitoring, making them integral to effective disease management.

The region also benefits from a robust digital health ecosystem, with widespread smartphone penetration, mobile health application usage, and EHR integration that facilitate the adoption of connected devices. Supportive reimbursement frameworks further incentivize both patients and providers to adopt these solutions. For example, in April 2024, Insulet’s Omnipod 5 received approval from Health Canada. This automated insulin delivery (AID) system integrates with continuous glucose monitoring (CGM), features a tubeless wearable design, and can be controlled via smartphone, offering patients a highly personalized, convenient alternative to traditional injections.

In addition, regulatory agencies such as the FDA and Health Canada have established clear pathways for connected and digital health devices, accelerating innovation and market entry. The presence of leading device manufacturers, strong venture funding in health tech, and ongoing R&D collaborations further reinforce North America’s leadership position.

The broader healthcare landscape is also shifting toward patient-centric models, emphasizing convenience, personalization, and improved outcomes. Connected devices enable remote monitoring, virtual consultations, and data-driven therapy adjustments, which not only empower patients to manage chronic conditions more effectively but also reduce the burden on healthcare facilities.

Taken together, the combination of technological readiness, supportive policy frameworks, and a rising chronic disease burden positions North America as the primary growth engine for the global connected drug delivery devices market during the forecast period.

Europe Connected Drug Delivery Devices Market Trends

Europe is expected to hold the second-largest share of the connected drug delivery devices market in 2024, driven by strong regulatory support, rising prevalence of chronic diseases, and increasing adoption of digital health initiatives across the region. The European Medicines Agency (EMA) and regional health authorities have been actively promoting the integration of digital therapeutics, connected devices, and data-driven care models into mainstream healthcare, creating a supportive environment for adoption.

The prevalence of chronic conditions such as diabetes, asthma, and COPD continues to rise in Europe, boosting demand for smart inhalers, connected insulin pens, and wearable injectors. For instance, according to the International Diabetes Federation (2023), more than 61 million people in Europe live with diabetes, making connected insulin delivery devices a critical tool for long-term disease management.

The region is also witnessing strong uptake of mobile health apps and telemedicine, supported by EU-wide digital health strategies such as the European Health Data Space (EHDS), which fosters secure sharing of patient data across borders. Countries like Germany, the UK, and France are leading adopters, with initiatives such as Germany’s DiGA (Digital Health Applications) reimbursement framework, which allows certain digital health tools to be prescribed and reimbursed by statutory health insurers.

In terms of innovation, several European device makers and research institutions are advancing connected drug delivery platforms integrated with AI and data analytics, enhancing the personalization of care. Moreover, strong public-private partnerships and EU funding for digital health transformation are fueling market growth.

Additionally, strong collaborations between pharma companies, medtech firms, and digital health startups across countries like Germany, the U.K., and France are accelerating product launches and adoption. For instance, in July 2025, Medtronic plc. announced that it had received CE Mark in Europe to expand indications of the MiniMed™ 780G system for individuals aged 2 years and older, during pregnancy, and for those with type 2 insulin-requiring diabetes.

Overall, Europe’s combination of policy support, high chronic disease prevalence, and digital health maturity positions it as a key growth region, second only to North America, in the global connected drug delivery devices market.

Asia-Pacific Connected Drug Delivery Devices Market Trends

The Asia-Pacific (APAC) region is projected to be the fastest-growing market for connected drug delivery devices, driven by a large patient pool, rising chronic disease burden, and rapid digital health adoption across emerging economies. Countries such as China, Japan, South Korea, and India are at the forefront of adoption, supported by improving healthcare infrastructure and a strong government focus on digital health integration.

The prevalence of chronic diseases is rising sharply in APAC. For example, the International Diabetes Federation (2023) reported that China alone accounts for over 140 million people with diabetes, representing the world’s largest diabetic population. Similarly, increasing cases of asthma, COPD, and cardiovascular diseases are accelerating demand for connected inhalers, insulin pens, and smart injectors across the region.

Government-driven initiatives such as China’s Healthy China 2030 plan, Japan’s digital health acceleration programs, and India’s National Digital Health Mission (NDHM) are creating strong foundations for the integration of connected devices into mainstream healthcare. Japan, in particular, has shown early adoption of connected insulin delivery systems and remote monitoring platforms, supported by its aging population and high healthcare technology penetration.

The APAC market is also benefiting from the increasing use of mobile health apps, wearable sensors, and telemedicine platforms, which seamlessly integrate with connected drug delivery devices. Local manufacturers are actively collaborating with multinational device makers to expand access to affordable solutions tailored for cost-sensitive markets.

With its large patient base, rapid digitalization of healthcare, and strong government initiatives, APAC is expected to be the fastest-growing region in the global connected drug delivery devices market, presenting significant opportunities for both established players and new entrants.

Who are the major players in the connected drug delivery devices market?

The following are the leading companies in the connected drug delivery devices market. These companies collectively hold the largest market share and dictate industry trends.

• Findair Sp. z o. o..
• Adherium
• Propeller Health.
• West Pharmaceutical Services, Inc.
• BIOCORP
• Phillips-Medisize
• Merck KGaA
• Novo Nordisk A/S
• Medtronic
• Tandem Diabetes Care, Inc.
• Ypsomed
• Teva Pharmaceutical Industries Ltd.
• Elcam Medical
• Cohero Health, Inc.
• BD
• Others

How is the competitive landscape shaping the connected drug delivery devices market?

The competitive landscape of the connected drug delivery devices market is evolving rapidly, shaped by a mix of established medtech and pharmaceutical companies, alongside emerging digital health startups. The market is currently moderately concentrated, with leading players such as Medtronic, Insulet, AstraZeneca, Novartis, and Adherium driving growth through strategic collaborations, product launches, and digital integration. These companies leverage their strong R&D capabilities and global distribution networks to maintain dominance, particularly in connected insulin pens, wearable injectors, and smart inhalers. At the same time, startups and mid-sized firms are intensifying competition by introducing niche innovations such as add-on smart sensors, Bluetooth-enabled devices, and AI-powered adherence platforms. Partnerships between pharma companies and digital health providers are also shaping the competitive dynamics, as the industry increasingly moves toward holistic, patient-centric care models. Overall, while a few large players hold significant market share, the space remains dynamic and open to disruption, with growing investment and technological innovation expected to reduce concentration and expand competition over time.

Recent Developmental Activities in the Connected Drug Delivery Devices Market

• In April 2025, Dexcom received FDA clearance for the G7 15-Day sensor, which boasts extended wear time and enhanced accuracy for diabetes management.
• In March 2025, Enable Injections obtained EU MDR CE-mark for the enFuse Syringe Transfer System, facilitating at-home administration of biologic therapies.
• In December 2024, the US FDA granted tentative approval for Lasix ONYU, a home-use furosemide micropump developed by Gerresheimer's partner SQ Innovation for treating fluid overload in congestive heart failure patients.
• In January 2024, BIOCORP obtained FDA 510(k) clearance for SoloSmart (a smart cap for Sanofi’s SoloStar insulin pens).

Connected Drug Delivery Devices Market Segmentation

Connected Drug Delivery Devices by Product Type Exposure

• Connected Sensors
  • Connected Inhaler Sensors
  • Connectable Injection Sensor
• Integrated Connected Devices
  • Connected Inhaler Devices
  • Connected Injectable Devices

Connected Drug Delivery Devices Technology Exposure

• Bluetooth
• Near-Field Communication (NFC)
• Others

Connected Drug Delivery Devices End-Users Exposure

• Hospitals & Clinics
• Homecare Settings
• Others

Connected Drug Delivery Devices Geography Exposure

• North America Connected Drug Delivery Devices Market
  • United States Connected Drug Delivery Devices Market
  • Canada Connected Drug Delivery Devices Market
  • Mexico Connected Drug Delivery Devices Market
• Europe Connected Drug Delivery Devices Market
  • United Kingdom Connected Drug Delivery Devices Market
  • Germany Connected Drug Delivery Devices Market
  • France Connected Drug Delivery Devices Market
  • Italy Connected Drug Delivery Devices Market
  • Spain Connected Drug Delivery Devices Market
  • Rest of Europe Connected Drug Delivery Devices Market
• Asia-Pacific Connected Drug Delivery Devices Market
  • China Connected Drug Delivery Devices Market
  • Japan Connected Drug Delivery Devices Market
  • India Connected Drug Delivery Devices Market
  • Australia Connected Drug Delivery Devices Market
  • South Korea Connected Drug Delivery Devices Market
  • Rest of Asia-Pacific Connected Drug Delivery Devices Market
• Rest of the World Connected Drug Delivery Devices Market
  • South America Connected Drug Delivery Devices Market
  • Middle East Connected Drug Delivery Devices Market
  • Africa Connected Drug Delivery Devices Market

Connected Drug Delivery Devices Market Recent Industry Trends and Milestones (2022-2025):

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations in connected drug delivery devices are transforming the way therapies are managed by enabling smarter, more personalized, and data-driven care. These devices integrate artificial intelligence with sensors and connectivity features to analyze patient data, detect medication adherence patterns, and predict potential non-compliance or adverse events. AI algorithms can process real-time information from connected insulin pens, smart inhalers, or injectors to optimize dosing schedules, reduce errors, and improve treatment outcomes. Moreover, AI enables predictive analytics that help healthcare providers tailor interventions for chronic conditions such as diabetes and asthma. By integrating with digital health platforms and remote monitoring systems, AI-powered connected drug delivery devices support proactive disease management, enhance patient engagement, and reduce hospitalizations, ultimately driving better clinical outcomes and expanding the value of connected therapeutics.

U.S. Tariff Impact Analysis on Connected Drug Delivery Devices Market:

The impact of U.S. tariffs on connected drug delivery devices is primarily seen in the form of increased production and import costs, which can affect both manufacturers and end-users. Since many components used in these devices, such as sensors, chips, and communication modules, are sourced globally, tariffs on imported medical device parts and electronics raise manufacturing expenses for companies operating in the U.S. market. This can lead to higher pricing for connected drug delivery devices, potentially slowing adoption among patients and healthcare providers. Additionally, tariffs may discourage foreign manufacturers from expanding in the U.S. or push them to localize production, influencing supply chain strategies. While demand for connected drug delivery devices remains strong due to rising chronic disease prevalence and digital health adoption, tariffs create economic pressure that could limit affordability, delay innovation cycles, and intensify competition among key players.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Startup Funding & Investment Trends

Key takeaways from the Connected Drug Delivery Devices market report study

• Market size analysis for the current connected drug delivery devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the connected drug delivery devices market.
• Various opportunities available for the other competitors in the connected drug delivery devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current connected drug delivery devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the connected drug delivery devices market growth in the future?